Back to Search
Start Over
EULAR 2020: Lilly's Taltz(r) (ixekizumab) Continues to Show Robust and Consistent Efficacy in Psoriatic Arthritis
- Source :
- Plus Company Updates. June 4, 2020
- Publication Year :
- 2020
-
Abstract
- INDIANAPOLIS: Eli Lilly and Company has issued the following press release: Taltz(r) (ixekizumab) demonstrated consistent efficacy and long-term potential to help patients with psoriatic arthritis (PsA) in new data to [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Plus Company Updates
- Publication Type :
- News
- Accession number :
- edsgcl.625759430